ESC 2024 | MATERHORN Trial: Transcatheter vs. Surgical Mitral Repair in Patients with Heart Failure and Secondary Mitral Regurgitation

European guidelines consider transcatheter therapy as an alternative for patients with secondary mitral regurgitation who are not surgical candidates (recommendation IIa). Based on this, a working group in Germany conducted a randomized, multicenter, non-inferiority study comparing mitral transcatheter edge-to-edge repair (TEER) with surgical repair.

Patients enrolled had secondary mitral regurgitation, ejection fraction greater than 20%, and remained symptomatic despite optimal medical treatment, but without associated valve disease.

Regarding the primary efficacy endpoint, which included a composite of death, heart failure (HF) rehospitalization, mitral reintervention, stroke, or ventricular assist device implantation, there was an advantage for the TEER arm, with greater event-free survival (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.33-1.44; p-non-inferiority <0.001).

In the safety evaluation, considering major adverse events (MAE) at 30 days, 54.8% of patients in the surgical group experienced MAE, compared to 14.9% in the TEER arm.

Read also: ESC 2024 | RESHAPE-HF2: MitraClip in Heart Failure and Moderate to Severe Mitral Regurgitation.

The study concluded that transcatheter therapy was noninferior in terms of clinical efficacy and showed a superior safety profile. Therefore, the authors suggest that this option should be considered for patients with secondary mitral regurgitation who are eligible for surgery, regardless of surgical risk.

Presented by Volker Rudolph at the Hot-Line Sessions, ESC Congress 2024, August 30-September 2, London, England.  


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

TAVR and Surgical Bailout: Temporal Trends and Clinical Implications

The evolution of transcatheter aortic valve replacement (TAVR), both regarding its planning and execution, has resulted in minimally invasive interventions with high safety levels....

Edge-to-Edge Repair in Atrial Secondary Tricuspid Regurgitation

Tricuspid regurgitation (TR) has been associated with higher morbimortality and a negative impact on quality of life.  In most cases, its main cause is a...

Percutaneous Treatment of Tricuspid Regurgitation with K-CLIP

Roughly 4% of the adult population presents tricuspid regurgitation (TR), a condition that might progress to severe or worse end-organ function, associated to hospitalizations...

PULSE Registry Subanalysis: Radial vs. Femoral Secondary Access

In view of its lower complications rate, the transfemoral approach is the most used in transcatheter aortic valve replacement (TAVR), vs. alternative access sites....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Acute Coronary Syndrome with Multivessel Disease: Best Revascularization Strategy

The gold standard treatment for acute coronary syndrome (ACS), especially acute myocardial infarction (AMI) is primary angioplasty (PCI). However, 40 to 70% of ACS...

Improved Ejection Fraction in Chronic Total Occlusion?

Chronic total occlusions (CTO) represent a significant challenge in the current clinical practice, seeing as CTO percutaneous coronary intervention (PCI) is complex and involves...

TAVR and Surgical Bailout: Temporal Trends and Clinical Implications

The evolution of transcatheter aortic valve replacement (TAVR), both regarding its planning and execution, has resulted in minimally invasive interventions with high safety levels....